Galderma Group AG
Anti Propionibacterium(P.) Acnes Activity of Epiduo® Gel Compared to Benzoyl Peroxide (BPO) 2.5% Gel
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 40
- Registration Number
- NCT01188538
- Locations
- 🇵🇱
Dermatologiczna Klinika Uzdrowiskowa, Iwonicz Zdrój, Poland
Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
- First Posted Date
- 2010-08-03
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 269
- Registration Number
- NCT01174030
- Locations
- 🇺🇸
Skin Specialty Group, New York, New York, United States
🇺🇸Central Dermatology, PC, Saint Louis, Missouri, United States
🇺🇸University of California at San Francisco, San Francisco, California, United States
Global Management of Facial Rejuvenation With a New Range of Hyaluronic Acid Dermal Fillers
- First Posted Date
- 2010-06-28
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 77
- Registration Number
- NCT01151436
- Locations
- 🇩🇪
Galderma investigational site, Darmstadt, Germany
A 7-year Follow up of All Subjects Incuded in Protocol 31GB0106
- Conditions
- Interventions
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 6
- Registration Number
- NCT01146275
- Locations
- 🇸🇪
Sophiahemmet, Stockholm, Sweden
🇸🇪Akademikliniken Öresund, Malmö, Sweden
🇸🇪Akademikliniken, Stockholm, Sweden
Swedish Macrolane Registry
- Conditions
- First Posted Date
- 2010-06-16
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 1300
- Registration Number
- NCT01145235
- Locations
- 🇸🇪
Dr Per Hedén, Stockholm, Sweden
Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin
- Conditions
- Interventions
- First Posted Date
- 2010-06-08
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 77
- Registration Number
- NCT01139047
- Locations
- 🇺🇸
Thomas J. Stephens & Associates, Inc., Colorado Springs, Colorado, United States
Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin
- Conditions
- Interventions
- First Posted Date
- 2010-06-08
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 80
- Registration Number
- NCT01139008
- Locations
- 🇺🇸
Thomas J. Stephens and Associates, Inc., Carrollton, Texas, United States
Epiduo Pediatric Acne Study
- Conditions
- Interventions
- First Posted Date
- 2010-06-07
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 285
- Registration Number
- NCT01138735
- Locations
- 🇺🇸
FXM Research Miramar, Miramar, Florida, United States
🇺🇸Henry Ford Health Systems Department of Dermatology, Detroit, Michigan, United States
🇺🇸Dermcenter PC - Somerset Skin Centre, Troy, Michigan, United States
Study to Evaluate Solesta for Treatment of Fecal Incontinence
- Conditions
- Interventions
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 115
- Registration Number
- NCT01110681
- Locations
- 🇨🇦
St. Paul's Hospital, Vancouver, Canada
🇩🇪Koloproktologische Praxis, Kiel, Germany
🇫🇷CHU-Hotel-Dieu, Nantes, France
Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne
- Conditions
- Interventions
- First Posted Date
- 2010-04-20
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 73
- Registration Number
- NCT01106807
- Locations
- 🇺🇸
J & S Studies, Bryan, Texas, United States
🇺🇸Cetero, Fargo, North Dakota, United States
🇺🇸Burke Pharmaceuticals, Hot Springs, Arkansas, United States